BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270122
DTSTAMP:20261002T122815Z
CREATED:20261002T122815Z
LAST-MODIFIED:20261002T122815Z
UID:44487-1800316800-1800575999@www.pharmajournalist.com
SUMMARY:5th Ophthalmic Drug Delivery Summit
DESCRIPTION:The 5th Ophthalmic Drug Delivery Summit is where the innovators behind the next generation of ocular therapies come together to solve one critical challenge: getting the right therapy to the right place in the eye. \nHear directly from leaders at Kodiak Sciences\, Re-Vana Therapeutics\, Ripple Therapeutics\, Eli Lilly\, Genentech\, Sanofi\, Astellas\, Apellis\, Beacon Therapeutics\, Kriya Therapeutics and more as they share the latest thinking on long-acting therapies\, novel delivery routes\, gene and cell therapy\, translational science and drug-device integration. \nWith clinical validation and investment accelerating across the field\, this industry-focused\, modality and indication-agnostic meeting offers a timely opportunity to benchmark emerging technologies\, learn from development successes and setbacks\, and connect with the experts tackling the biggest barriers to effective ocular delivery. \nExpect candid lessons\, emerging strategies and cross-functional perspectives spanning delivery\, formulation\, devices\, CMC\, clinical development\, regulatory strategy and commercialization. \nDon’t miss the only industry-focused\, modality\, and indication-agnostic forum dedicated to ophthalmic drug delivery. \nTo know more visit: https://ter.li/4m4gw2gg
URL:https://www.pharmajournalist.com/event/5th-ophthalmic-drug-delivery-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf San Francisco\, 555 North Point St\, San Francisco\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20260925T061157Z
CREATED:20260925T060703Z
LAST-MODIFIED:20260925T061157Z
UID:44399-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:Muscular Disorders Drug Development Summit
DESCRIPTION:Muscular Disorders Drug Development Summit | January 26-28\, 2027 | Boston\, MA \nThe muscular disease field is entering a pivotal new chapter. Following a year of significant debate around Sarepta’s Elevidys\, the industry is rapidly evolving as a new wave of gene therapies\, RNA medicines\, stem cell therapies\, and small molecules advance through development. With anticipated regulatory milestones from companies including Regenxbio\, Capricor\, and Avidity Biosciences\, alongside growing investment and renewed pharmaceutical interest\, momentum has never been stronger across muscular dystrophies\, Pompe disease\, and related myopathies. \nThe inaugural Muscular Disorders Drug Development Summit is the only industry-focused forum dedicated to helping biopharma leaders accelerate the translation\, clinical development\, and delivery of next-generation therapies for muscle disorders. \nBe the first to access the newly launched event program. \nAcross three days of expert-led presentations\, interactive discussion\, and dedicated networking\, attendees will: \n\nDiscover lessons learned from approved and late-stage muscular disease therapies\nExplore emerging modalities beyond traditional gene therapy\nAdvance biomarker strategies and functional outcome assessments\nInnovate targeted delivery approaches to improve efficacy and reduce off-target effects\nLeverage real-world data to identify meaningful\, patient-relevant endpoints\nBuild partnerships that can accelerate clinical and commercial success\n\nJoin 60+ industry experts and leading organizations including Servier\, Dyne Therapeutics\, Sanofi\, Biogen\, and Avidity Biosciences for three days of collaboration focused on overcoming the biggest challenges in muscular disorder drug development. \nWhether you’re advancing therapies for DMD\, FSHD\, DM\, LGMD\, Pompe disease\, or other rare muscle disorders\, this is the must-attend meeting to benchmark strategies\, forge new partnerships\, and help bring transformative treatments to patients faster. \nExplore the Full Agenda | Register Your Place
URL:https://www.pharmajournalist.com/event/muscular-disorders-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20261002T121356Z
CREATED:20261002T121356Z
LAST-MODIFIED:20261002T121356Z
UID:44484-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:2nd Non-Opioid Pain Therapeutics Summit
DESCRIPTION:One year on from Vertex Pharmaceuticals’ milestone JOURNAVX® approval\, making history as the first new class of pain medicine in decades\, non-opioid pain R&D has skyrocketed as one of biopharma’s hottest areas for innovation and investment\, projected to hit $124bn by 2034. \nBringing together 150+ senior leaders across pain biology\, drug discovery\, translational science\, clinical development\, medical affairs\, business development\, venture capital\, and patient advocacy\, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals\, Eli Lilly\, AbbVie\, Grünenthal\, Xenon Pharmaceuticals\, Levicept\, Tonix Pharma\, Maxona Pharmaceuticals\, 4E Therapeutics\, NIH\, Harvard Medical School\, and leading investment firms to explore emerging mechanisms\, new clinical data\, trial design innovations\, placebo mitigation strategies\, translational models\, patient-centered development approaches\, and the investment trends shaping the future of pain therapeutics. \nTo know more visit: https://ter.li/9cl7g1gn
URL:https://www.pharmajournalist.com/event/2nd-non-opioid-pain-therapeutics-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270312
DTSTAMP:20260929T183930Z
CREATED:20260925T071331Z
LAST-MODIFIED:20260929T183930Z
UID:44434-1804464000-1804809599@www.pharmajournalist.com
SUMMARY:17th World ADC London
DESCRIPTION:17th World ADC London | 8-11th March 2027 | London\, UK\nThe preliminary agenda for the 17th World ADC London has now been released\, offering a first look at the science\, strategic insights and partnerships set to shape the future of antibody-drug conjugate (ADC) development. Taking place from 8-11th March 2027 in London\, the event will bring together more than 700 leaders from biopharma\, biotech\, academia\, investment and solution provider organisations for Europe’s largest annual gathering dedicated to the ADC community. \nAs ADCs continue to gain momentum across oncology\, the industry faces a new generation of challenges and opportunities. From overcoming resistance mechanisms and improving patient response rates to advancing differentiated designs and scaling manufacturing\, the need for collaboration and knowledge-sharing has never been greater. World ADC London provides a unique platform for the community to exchange ideas\, learn from emerging data and explore the strategies driving the next wave of innovation. \nThe programme spans the full ADC development journey\, covering discovery\, preclinical and translational development\, clinical strategy\, process and analytical development\, and manufacturing. Attendees will hear from more than 90 industry experts as they share scientific breakthroughs\, lessons learned and practical approaches to accelerating the development of safer\, more effective ADC therapies. \nMore than just a scientific meeting\, World ADC London is recognised as the annual meeting point for the global ADC community. For 17 years\, it has brought together established leaders\, emerging biotech companies\, investors and technology innovators in an environment designed to foster meaningful connections and productive discussions. Whether you are looking to benchmark your strategy\, identify new partners\, discover enabling technologies or gain a broader understanding of the competitive landscape\, the event offers unrivalled opportunities to connect with the people shaping the field. \nWith extensive networking opportunities\, dedicated partnering experiences and cutting-edge scientific content\, World ADC London remains the essential forum for anyone involved in ADC development. The newly released preliminary agenda provides an early opportunity to explore the discussions\, discoveries and connections that will help define the next chapter of ADC innovation and ultimately improve outcomes for patients worldwide. \nView the agenda here: https://ter.li/orip0z61
URL:https://www.pharmajournalist.com/event/17th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR